| Medical and Health Sciences | 2021-2025 | 306 | US 109 | 99.94 |
| Oncology | Lifetime | 285 | US 163 | 99.53 |
| Hepatology | Lifetime | 644 | US 230 | 90.19 |
| Oncology | 2021-2025 | 34 | US 11 | 99.81 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 143 | US 45 | 99.02 |
| Surgery | 2021-2025 | 277 | US 114 | 98.20 |
| Cancer Research | 2021-2025 | 114 | US 44 | 94.74 |
| Pathology and Forensic Medicine | 2021-2025 | 226 | US 82 | 93.59 |
| Hepatology | 2021-2025 | 317 | US 86 | 76.54 |
| Pancreatic and Hepatic Oncology Research | Lifetime | 155 | US 87 | 99.46 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | Lifetime | 91 | US 43 | 99.48 |
| Colorectal Cancer Treatments and Studies | Lifetime | 107 | US 48 | 99.58 |
| Gastric Cancer Management and Outcomes | Lifetime | 330 | US 122 | 99.21 |
| Cancer Treatment and Pharmacology | Lifetime | 254 | US 141 | 99.20 |
| Genetic factors in colorectal cancer | Lifetime | 334 | US 164 | 98.68 |
| Cancer Genomics and Diagnostics | Lifetime | 671 | US 367 | 98.78 |
| Hepatocellular Carcinoma Treatment and Prognosis | Lifetime | 411 | US 117 | 98.64 |
| Colorectal and Anal Carcinomas | Lifetime | 351 | US 138 | 97.75 |
| Cancer Mechanisms and Therapy | Lifetime | 310 | US 146 | 96.76 |
| Neuroendocrine Tumor Research Advances | Lifetime | 729 | US 287 | 97.69 |
| Cancer Research and Treatments | Lifetime | 765 | US 405 | 96.49 |
| HER2/EGFR in Cancer Research | Lifetime | 608 | US 278 | 97.56 |
| Fibroblast Growth Factor Research | Lifetime | 441 | US 189 | 94.45 |
| Economic and Financial Impacts of Cancer | Lifetime | 958 | US 607 | 91.83 |
| Pancreatic and Hepatic Oncology Research | 2021-2025 | 24 | US 8 | 99.55 |
| Cancer Genomics and Diagnostics | 2021-2025 | 55 | US 27 | 99.46 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 20 | US 7 | 99.73 |
| Gastric Cancer Management and Outcomes | 2021-2025 | 39 | US 6 | 99.52 |
| Genetic factors in colorectal cancer | 2021-2025 | 23 | US 9 | 99.07 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | 2021-2025 | 48 | US 15 | 98.77 |
| Cancer Treatment and Pharmacology | 2021-2025 | 90 | US 31 | 98.27 |
| HER2/EGFR in Cancer Research | 2021-2025 | 114 | US 40 | 98.26 |
| Lung Cancer Treatments and Mutations | 2021-2025 | 638 | US 213 | 96.08 |
| Neuroendocrine Tumor Research Advances | 2021-2025 | 439 | US 111 | 91.91 |
| Fibroblast Growth Factor Research | 2021-2025 | 87 | US 36 | 88.22 |
| Gallbladder and Bile Duct Disorders | 2021-2025 | 561 | US 108 | 91.73 |
| Advanced Breast Cancer Therapies | 2021-2025 | 481 | US 171 | 91.14 |
| Economic and Financial Impacts of Cancer | 2021-2025 | 450 | US 285 | 89.05 |
| Pediatric Hepatobiliary Diseases and Treatments | 2021-2025 | 507 | US 110 | 86.48 |
| Multiple and Secondary Primary Cancers | 2021-2025 | 923 | US 324 | 67.08 |
